Back to Search
Start Over
ASSESSMENT OF THE DIFFERENCES IN PHARMACOKINETICS AND PHARMACODYNAMICS BETWEEN FOUR DISTINCT FORMULATIONS OF TRIAMCINOLONE ACETONIDE
- Source :
- Retina. 33:522-531
- Publication Year :
- 2013
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2013.
-
Abstract
- To compare the durability of Kenalog, Trivaris, Triesence, and compounding pharmacy preservative-free triamcinolone acetonide in pigmented rabbits with syneretic vitreous using direct visualization, pharmacodynamics, and pharmacokinetics.Twenty-five Dutch-belted rabbits were used. Pharmacokinetic experiment: Rabbits were intravitreally injected with one of four 4-mg triamcinolone acetonide formulations. Wide-field imaging was serially performed to document residual drug mass. Pharmacodynamics experiment: Four triamcinolone acetonide groups and one control group received intravitreal recombinant human vascular endothelial growth factor 165 every 2 weeks and were followed with fluorescein angiography to assess vascular endothelial growth factor retinal vasculopathy as a measure of residual steroid effect. Particle size of the formulations was measured with Mastersizer 2000.Remaining triamcinolone acetonide mass after 19 weeks: 12,091 ± 2,512 pixels for the Kenalog group, 1,307.36 ± 695.57 for Trivaris, 5577 ± 1477 for Triesence, and 1,535 ± 329 for compounded preservative-free triamcinolone acetonide. Kenalog suppressed recombinant human vascular endothelial growth factor-induced retinopathy more effectively than the other triamcinolone acetonide groups at Week 39, the final time point assessed. Particle size (90th percentile) was 47 μm for Kenalog, 26 μm for Triesence, and 22 μm for both compounded preservative-free triamcinolone acetonide and Trivaris.Triamcinolone acetonide formulations do not have the same pharmacokinetics/pharmacodynamics. Kenalog has the longest vitreous visibility and durability. Particle size appears to correlate with efficacy and durability.
- Subjects :
- Vascular Endothelial Growth Factor A
Triamcinolone acetonide
genetic structures
Drug Compounding
Biological Availability
Retinal Neovascularization
Pharmacology
Triamcinolone Acetonide
Retinal neovascularization
Pharmacokinetics
medicine
Animals
Fluorescein Angiography
Particle Size
Glucocorticoids
Drug compounding
business.industry
Preservatives, Pharmaceutical
General Medicine
Recombinant Proteins
eye diseases
Vitreous Body
Ophthalmology
Solubility
Pharmacodynamics
Intravitreal Injections
Rabbits
sense organs
business
Half-Life
medicine.drug
Biological availability
Subjects
Details
- ISSN :
- 0275004X
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- Retina
- Accession number :
- edsair.doi.dedup.....9dbb7e6241d1d5854ee1dddcf14d1956